Update on a real-world study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
Update on a real-world study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
Scand J Urol. 2020 Apr 14;:1-2
Authors: Alghazali M, Löfgren A, Cheng N, Fagerlund K, Bjartell A
PMID: 32285739 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
More News: Cancer | Cancer & Oncology | PET Scan | Prostate Cancer | Study | Sweden Health | Urology & Nephrology